FEL D 1-specific human IGE class switched to IGE monoclonal antibodies
Ended Purchase Order Awarded Last action
- Contract number
- 75F40124P00438
- Awardee
-
Iggenix, Inc. UEI HBP9HFYHB3Q4
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $100,000
Award facts
- Opportunity
-
- Fel d 1-specific capture and biotin-labeled detection monoclonal antibodies suitable for use in Enzyme Linked Immunosorbent Assay (ELISA/ImmunoEnzymetric Assay (IEMA) Solicitation · FDARFQ125149 · Posted Aug 23, 2024
- Contract value 100% obligated
- $100,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- South San Francisco, CA 94080, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $100,000 |
About this award
The Food and Drug Administration's Center for Biologics Evaluation and Research awarded a $100,000 firm fixed-price purchase order to Iggenix, Inc. on September 4, 2024, for the procurement of Fel d 1-specific monoclonal antibodies. The contract calls for the delivery of 3 grams of human monoclonal antibody specific to a first epitope on the cat allergen Fel d 1 and 1 gram of biotinylated human monoclonal antibody targeting a second distinct epitope on Fel d 1. These antibodies are intended for use in enzyme-linked immunosorbent assay (ELISA) or immunoenzymetric assay (IEMA) applications. The contract was awarded with a firm fixed-price structure and no set-asides were employed in the competitive procurement process.
Iggenix, Inc., located in South San Francisco, California, was selected as the prime contractor following an open competition announced on August 23, 2024, with quotes due by August 30, 2024. The award has an ultimate completion date of September 26, 2025. This procurement supports FDA's regulatory mission in biologics evaluation and research, enabling the agency to develop standardized reference materials for allergen detection and characterization purposes. No subcontractors were identified in the award documentation.
Quick answers
Who was awarded contract 75F40124P00438?
75F40124P00438 was awarded to Iggenix, Inc. by Food and Drug Administration (Department of Health and Human Services) on September 4, 2024.
How much is contract 75F40124P00438 worth?
The government has obligated $100,000 on 75F40124P00438.
Was contract 75F40124P00438 competed?
The extent of competition for 75F40124P00438 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award